A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments (PROCEED)

April 13, 2026 updated by: H. Lundbeck A/S

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-finding Trial of Lu AG09222 for the Prevention of Migraine in Participants With Unsuccessful Prior Preventive Treatments

The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
874

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Bulgaria
      • Plovdiv, Bulgaria, 4000
        • MC Nevrocentrum
      • Plovdiv, Bulgaria, 4002
        • University Multiprofile Hospital for Active Treatment Sveti Georgi
      • Rousse, Bulgaria, 7000
        • MC Rusemed-OOD
    • Sofiiska
      • Sofia, Sofiiska, Bulgaria, 1680
        • Diagnostic Consultative Center Convex Ltd
  • Czechia
      • Hradec Králové, Czechia, 500 03
        • Dr. Radomir Talab MD, Office of
      • Pilsen, Czechia, 30100
        • Neuros s.r.o
      • Prague, Czechia, 18600
        • Institut neuropsychiatricke pece
      • Prague, Czechia, 150 00
        • Praglandia s.r.o
      • Prague, Czechia, 100 00
        • Clintrial s. r. o.
      • Prague, Czechia, 12000
        • DADO Medical s.r.o.
      • Prague, Czechia, 15500
        • Axon Clinical s r.o
      • Prague, Czechia, 160 00
        • Neurologicka ordinace FORBELI sro
      • Slezská Ostrava, Czechia, 710 00
        • Neurologicka ambulance
      • Zlín, Czechia, 76001
        • NeuroMed Zlin s.r.o.
    • Pardubický kraj
      • Litomyšl, Pardubický kraj, Czechia, 57001
        • Neurosanatio s.r.o.
  • Denmark
      • Copenhagen, Denmark, 2400
        • Bispebjerg Hospital - Region Capital
      • Glostrup Municipality, Denmark, 2600
        • Glostrup Hospital
  • France
      • Bron, France, 69500
        • Centre Hospitalier Universitaire de Lyon, Hopital Pierre Wertheimer
      • Clermont-Ferrand Cedex1, France, 63003
        • Centre Hospitalier Universitaire de Clermont Ferrand - Gabriel Montpied
      • Lille, France, 59037
        • Centre Hospitalier Regional Universitaire de Lille - Hopital Roger Salengro
      • Marseille, France, 13385
        • Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital de La Timone
      • Paris, France, 75010
        • Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Lariboisiere
      • Toulouse, France, 31059
        • Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital Pierre-Paul Riquet
  • Georgia
      • Tbilisi, Georgia, 0179
        • S. Khechinashvili University Hospital
      • Tbilisi, Georgia, 0159
        • JSC K. Eristavi National Center of Experimental and Clinical Surgery
      • Tbilisi, Georgia, 0160
        • Aversi Clinic
      • Tbilisi, Georgia, 0101
        • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center
      • Tbilisi, Georgia, 0102
        • Caucasus Medical Center Ltd
      • Tbilisi, Georgia, 0159
        • Archangel St Michael Multiprofile Clinical Hospital
      • Tbilisi, Georgia, 0159
        • Jo Ann Medical Center
      • Tbilisi, Georgia, 0160
        • MD Georgia Staff Physician MediClub Georgia
  • Germany
      • Berlin, Germany, 10117
        • Charite - Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)
      • Böblingen, Germany, 71034
        • Studienzentrum Dr. Bischof GmbH
      • Ebersberg, Germany, 85560
        • Klinik Haag i. OB
      • Frankfurt, Germany, 65929
        • Headache Center Frankfurt
      • Hanover, Germany, 30449
        • Siteworks - Hannover
      • Heidelberg, Germany, 69115
        • Siteworks - Heidelberg
  • Hungary
      • Tatabánya, Hungary, 2800
        • Komarom-Esztergom Varmegyei Szent Borbala Korhaz
    • Central Hungary (Közép-Magyarország)
      • Budapest, Central Hungary (Közép-Magyarország), Hungary, 1044
        • S-Medicon Kft.
  • Japan
      • Tokyo, Japan, 160-8582
        • Keio University Hospital
    • Fukuoka
      • Kasuga-shi, Fukuoka, Japan, 816-0802
        • Jinnouchi Neurosurgery Clinic
      • Kasuga-shi, Fukuoka, Japan, 816-0824
        • Ikeda Neurosurgery Clinic
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 060-0061
        • Nakamura Memorial Hospital
    • Ibaraki
      • Mito, Ibaraki, Japan, 310-0015
        • Mito Kyodo General Hospital
    • Iwate
      • Morioka, Iwate, Japan, 020-8505
        • Iwate Medical University Uchimaru Medical Center
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japan, 890-0052
        • Tanaka Neurosurgery & Headache Clinic
      • Kagoshima, Kagoshima-ken, Japan, 892-0842
        • Atsuchi Neurosurgical Hospital
    • Kanagawa
      • Fujisawa-shi, Kanagawa, Japan, 252-0816
        • Shonan Keiiku Hospital
    • Miyagi
      • Sendai, Miyagi, Japan, 982-0014
        • Sendai Headache and Neurology Clinic Medical Corporation
    • Osaka
      • Osaka, Osaka, Japan, 556-0017
        • Tominaga Hospital
    • Saitama
      • Iruma-gun, Saitama, Japan, 350-0495
        • Saitama Medical University Hospital
    • Shizuoka
      • Shizuoka, Shizuoka, Japan, 420-0853
        • Japanese Red Cross Shizuoka Hospital
    • Tochigi
      • Shimotsuga-Gun, Tochigi, Japan, 321-0293
        • Dokkyo Medical University Hospital
    • Tokyo
      • Minato-ku, Tokyo, Japan, 108-8642
        • Kitasato University Kitasato Institute Hospital
      • Minato-ku, Tokyo, Japan, 108-0075
        • Shinagawa Strings Clinic
  • Lithuania
      • Kaunas, Lithuania, 50161
        • Hospital of Lithuanian University of Health Sciences Kaunas
      • Klaipėda, Lithuania, LT-92288
        • Klaipeda¿s University Hospital
      • Tauragė, Lithuania, 72250
        • Medicum Centrum
      • Vilnius, Lithuania, 08661
        • Vilniaus Universiteto Medicinos Fakultetas - Neurologijos ir Neurochirurgijos Klinika - Neurologi...
  • Poland
      • Bydgoszcz, Poland, 85-796
        • Centrum Medczyne Pratia Bydgoszcz
      • Elblag, Poland, 82-300
        • Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka partnerska
      • Krakow, Poland, 30-727
        • Pratia MCM Krakow
      • Ksawerów, Poland, 95-054
        • Centrum Opieki Zdrowotnej OrkanMed
      • Lodz, Poland, 90-347
        • AppleTreeClinics Network Sp. z o.o.
      • Lublin, Poland, 20-701
        • Centrum Medyczne Hope Clinic Sebastian Szklener
      • Lublin, Poland, 20-064
        • Clinirem Sp. z o.o.
      • Lublin, Poland, 20-582
        • Indywidualna Praktyka Lekarska Dr hab. n. med. Anna Szczepanska-Szerej
      • Nowa Sól, Poland, 67-100
        • Twoja Przychodnia NCM
      • Oświęcim, Poland, 32-600
        • Instytut Zdrowia dr Boczarska-Jedynak
      • Plewiska, Poland, 62-064
        • Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Badan Klinicznych im. dr n. med. Hanki...
      • Sochaczew, Poland, 96-500
        • RCMed Oddzial Sochaczew
      • Warsaw, Poland, 02-172
        • MTZ Clinical Research Powered by Pratia
      • Wroclaw, Poland, 52-210
        • MIGRE Polskie Centrum Leczenia Migreny
      • Zabrze, Poland, 41-807
        • Clinhouse Centrum Medyczne
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Poland, 61-485
        • Centrum Medyczne HCP sp. z o.o
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Poland, 31-156
        • LANDA Specjalistyczne Gabinety Lekarskie
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Poland, 01-684
        • Centrum Medyczne NeuroProtect
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Poland, 40-749
        • NEURO-CARE Sp. z o.o. Sp. Komandytowa
  • Romania
      • Bucharest, Romania, 30463
        • Policlinica CCBR S.R.L.
      • Constanța, Romania, 900591
        • The Emergency County Clinical Hospital St. Andrew Constanta
    • Judet Arges
      • Campulung Muscel, Judet Arges, Romania, 115100
        • Sc Clubul Sanatatii S.R.L.
  • Slovakia
      • Banská Bystrica, Slovakia, 974 04
        • Private Practice - Dr. Beáta Dupejová
      • Bardejov, Slovakia, 085 01
        • IN MEDIC s.r.o
      • Dubnica nad Váhom, Slovakia, 018 41
        • KONZILIUM s.r.o.
      • Prešov, Slovakia, 08001
        • SANERA, s.r.o.
  • Spain
      • Alicante, Spain, 03010
        • Hospital General Universitario de Alicante
      • Barcelona, Spain, 08035
        • Hospital Universitario Vall d'Hebron
      • Barcelona, Spain, 08003
        • Parc de Salut Mar - Hospital del Mar
      • Madrid, Spain, 28022
        • Clinica Universidad de Navarra
      • Pamplona, Spain, 31008
        • Clinica Universidad de Navarra
      • Valencia, Spain, 46026
        • Hospital Universitario La Fe de Valencia
      • Valencia, Spain, 46010
        • Hospital Clinico Universitario de Valencia (Instituto de Investigacion Sanitaria Incliva)
  • United States
    • Alabama
      • Hoover, Alabama, United States, 35244-5700
        • Accel Research Sites Network - Neurology and Neurodiagnostic of Alabama
    • California
      • Carlsbad, California, United States, 92011
        • Profound Research - Neurology Center of Southern California
      • Fullerton, California, United States, 92835
        • Neurology Center of North Orange County
      • Los Alamitos, California, United States, 90720
        • CenExel CNS
      • Sherman Oaks, California, United States, 91403
        • Asclepes Research Centers
    • Connecticut
      • Stamford, Connecticut, United States, 06905
        • Ki Health Partners LLC DBA New England Institute for Clinical Research
    • Florida
      • Clermont, Florida, United States, 34711
        • K2 Medical Research - Winter Garden
      • Jacksonville, Florida, United States, 32256
        • Clinical Neuroscience Solutions, Inc.
      • Maitland, Florida, United States, 32751
        • K2 Medical Research, LLC - Maitland
      • Naples, Florida, United States, 34105
        • Aqualane Clinical Research
      • Tampa, Florida, United States, 33607
        • K2 Medical Research Tampa LLC
      • West Palm Beach, Florida, United States, 33407
        • Premiere Research Institute Palm Beach
    • Iowa
      • Ames, Iowa, United States, 50010
        • Accellacare and McFarland Clinic
    • Missouri
      • Chesterfield, Missouri, United States, 63005
        • Clinical Research Professionals
      • Hazelwood, Missouri, United States, 63042
        • Healthcare Research Network
    • New York
      • Amherst, New York, United States, 14226
        • Dent Neurosciences Research Center, Inc.
      • Port Jefferson Station, New York, United States, 11776
        • North Suffolk Neurology, PC.
    • North Carolina
      • Cary, North Carolina, United States, 27518
        • Accellacare of Cary - Cary Medical Group
      • Greensboro, North Carolina, United States, 27405
        • Headache Wellness Center
      • Raleigh, North Carolina, United States, 27612
        • M3 Wake Research, Inc
      • Raleigh, North Carolina, United States, 27609
        • Raleigh Medical Group
      • Rocky Mount, North Carolina, United States, 27804
        • Accellacare of Rocky Mount
      • Winston-Salem, North Carolina, United States, 27103
        • Triad Neurological Associates
    • South Carolina
      • Mt. Pleasant, South Carolina, United States, 29464
        • Accellacare of Charleston
    • Tennessee
      • Bristol, Tennessee, United States, 37620
        • Internal Medicine and Pediatric Associates of Bristol, PC
    • Texas
      • Dallas, Texas, United States, 75251
        • Cedar Health Research, LLC
      • Sugar Land, Texas, United States, 77478
        • Mercury Clinical Research
    • Virginia
      • McLean, Virginia, United States, 22101
        • MedStar Health - Neurology Clinic at McLean

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Key Inclusion Criteria:

  • The participant has a diagnosis of migraine as defined by International Classification of Headache Disorders Third Edition (ICHD-3) guidelines confirmed at the Screening Visit.
  • The participant has a history of migraine onset ≥ 12 months prior to the Screening Visit.
  • The participant has a migraine onset at ≤50 years of age.
  • The participant has ≥4 migraine days per month for each month within the past 3 months prior to the Screening Visit.
  • The participant has documented evidence of treatment failure in the past 10 years of at least 1 to 4 (maximum) different migraine preventive medications.

Key Exclusion Criteria:

  • The participant has previously been dosed with an anti-pituitary adenylate cyclase-activating peptide (anti-PACAP treatment).
  • The participant has confounding and clinically significant pain syndromes.
  • The participant has a diagnosis of acute or active temporomandibular disorder.
  • The participant has a history or diagnosis of confounding headaches.

Additional protocol-defined criteria apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: Group A: Placebo SC (closed for recruitment)
Participants will receive 2 injections of placebo.
Drug: Placebo
Placebo matching to Lu AG09222 will be administered per the arm description
Experimental: Group B: Lu AG09222 SC (closed for recruitment)
Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.
Drug: Placebo
Placebo matching to Lu AG09222 will be administered per the arm description
Drug: Lu AG09222
Lu AG09222 will be administered per the arm description.
Experimental: Group C: Lu AG09222 SC (closed for recruitment)
Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.
Drug: Placebo
Placebo matching to Lu AG09222 will be administered per the arm description
Drug: Lu AG09222
Lu AG09222 will be administered per the arm description.
Experimental: Group D: Lu AG09222 SC (closed for recruitment)
Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.
Drug: Placebo
Placebo matching to Lu AG09222 will be administered per the arm description
Drug: Lu AG09222
Lu AG09222 will be administered per the arm description.
Experimental: Group E: Lu AG09222 SC (closed for recruitment)
Participants will receive 2 injections, each containing Lu AG09222.
Drug: Lu AG09222
Lu AG09222 will be administered per the arm description.
Placebo Comparator: Group F: Placebo IV
Participants will receive placebo by intravenous (IV) infusion.
Drug: Placebo
Placebo matching to Lu AG09222 will be administered per the arm description
Experimental: Group G: Lu AG09222 IV
Participants will receive Lu AG09222 by IV infusion.
Drug: Lu AG09222
Lu AG09222 will be administered per the arm description.
Experimental: Group H: Lu AG09222 IV
Participants will receive Lu AG09222 by IV infusion.
Drug: Lu AG09222
Lu AG09222 will be administered per the arm description.
Experimental: Group I: Lu AG09222 IV
Participants will receive Lu AG09222 by IV infusion.
Drug: Lu AG09222
Lu AG09222 will be administered per the arm description.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Change From Baseline in the Number of Monthly Migraine Days (MMDs)
Time Frame: Baseline up to Week 12 (Weeks 1-12)
Baseline up to Week 12 (Weeks 1-12)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Change From Baseline in MMDs
Time Frame: Baseline up to Week 12 (Weeks 1-12)
Baseline up to Week 12 (Weeks 1-12)
Percentage of Participants With ≥50% Reduction From Baseline in MMDs
Time Frame: Baseline up to Week 12 (Weeks 1-12)
Baseline up to Week 12 (Weeks 1-12)
Percentage of Participants With ≥75% Reduction From Baseline in MMDs
Time Frame: Baseline up to Week 12 (Weeks 1-12)
Baseline up to Week 12 (Weeks 1-12)
Change from Baseline in the Number of Monthly Headache Days
Time Frame: Baseline up to Week 12 (Weeks 1-12)
Baseline up to Week 12 (Weeks 1-12)
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Time Frame: Up to Week 20
Up to Week 20
Number of Participants with Anti-drug Antibodies (ADA)
Time Frame: Up to Week 20
Up to Week 20

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
H. Lundbeck A/S

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Email contact via H. Lundbeck A/S, H. Lundbeck A/S

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 16, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 30, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 15, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 15, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 21, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 15, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 13, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 20297A
  • 2023-508821-28-00 (Other Identifier: EU Trial)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Migraine

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings